AbbVie Inc. $ABBV has marked a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for its new drug, Emrelis. Designed for adult patients with previously treated non-squamous non-small cell lung cancer (NSCLC), Emrelis is part of a growing class of antibody-drug conjugates (ADCs), offering a targeted therapeutic alternative to traditional chemotherapy.